



# ADDRESSING UNMET NEEDS IN ADVANCED ENDOMETRIAL CANCER

 THE LATEST ADVANCES  
FOR THE ONCOLOGY NURSE

**cec**  
ONCOLOGY

Presented by Creative Educational Concepts, LLC.  
Supported through independent educational grants  
from GlaxoSmithKline, Eisai, and Merck.

## Learning Objectives

- Identify the predictive biomarkers that allow for tailored treatment options for patients with endometrial cancer, exploring the role of the oncology nurse in molecular testing.
- Appraise recent clinical evidence on the safety and efficacy of immune checkpoint inhibitor monotherapy and combinatorial regimens for the treatment of advanced or recurrent endometrial cancer.
- Analyze the unique toxicities of immune checkpoint inhibitors for endometrial cancer and important considerations for both monitoring and managing adverse events.
- Use a case-based approach to recognize and address socioeconomic and racial disparities affecting health outcomes in endometrial cancer patients and how the oncology nurse can provide patient-centric care that is both efficacious and equitable.



**Sirithepphavanh S. Oliver, NP**

Nurse Practitioner  
Gynecologic Oncology  
Hospital of University of Pennsylvania  
Philadelphia, Pennsylvania



**Mary B. Welch, MS, FNP, AOCN**

GYN Oncology Nurse Practitioner/  
Nurse Navigator  
MemorialCare  
Long Beach Medical Center  
Long Beach, CA

## Faculty Disclosures

It is the policy of Creative Educational Concepts LLC (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers' bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

### Planner/Faculty

**Sirithhepphanh S. Oliver, NP**—has disclosed that she is on the Speakers Bureau for GlaxoSmithKline.

### Faculty

**Mary B. Welch, MS, FNP, AOCN**—has no relevant financial relationships to disclose in relation to the content of this activity.

### Peer Reviewer

**Julie George, NP**—has no relevant financial relationships to disclose in relation to the content of this activity.

### CEC Staff

**Tina L. Trieu, PharmD**—has no relevant financial relationships to disclose in relation to the content of this activity.

**Jessica Hall**—has no relevant financial relationships to disclose in relation to the content of this activity.

## Thank You

Presented by Creative Educational Concepts



*Supported through independent educational grants from  
GlaxoSmithKline, Eisai, and Merck.*

## Accreditation

- Nurses: 1.0 ANCC contact hour

<https://www.surveymonkey.com/r/Q8WPMQK>

